Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a report released on Friday. The brokerage set a “sell” rating on the stock.

Bio-Path Stock Down 12.5 %

Shares of BPTH stock opened at $0.63 on Friday. The business’s fifty day simple moving average is $0.89 and its 200-day simple moving average is $1.00. Bio-Path has a 12-month low of $0.59 and a 12-month high of $9.83.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.